Latest Headlines

Latest Headlines

Sequenom strikes liquid biopsy research deal with UC San Diego Moores

Sequenom has already made waves with its noninvasive prenatal diagnostic, revealing earlier this year that its technology could uncover signs of cancer in pregnant women. Now, the company is moving forward with its new liquid biopsy test, teaming up with the UC San Diego Moores Cancer Center to use its tool to monitor cancer patients and match them with a suitable therapy. 

Immatics, MD Anderson partner on a $60M immuno-oncology T-cell spinout

Harpreet Singh, the CSO and co-founder of Germany's Immatics Biotechnologies, has been splitting his time between Germany and Houston in order to set up a new biotech company that will collaborate with some top researchers at MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline.

Hospira and Cerner team up for infusion pump healthcare IT collaboration

Hospira and healthcare IT firm Cerner are joining forces to develop the companies' infusion pump information platform, building on previous efforts to better integrate Hospira's infusion pumps with Cerner's electronic medical record systems.

AstraZeneca continues I-O deal spree with PD-L1 combo trial hookup

AstraZeneca has struck its fourth immuno-oncology deal in as many weeks. The latest deal in the flurry of activity sees AstraZeneca hook up with Peregrine Pharmaceuticals to add another study to the burgeoning list of PD-L1 checkpoint inhibitor combination trials.

Actelion taps DKSH to break into Asia

Market-access contractor DKSH has signed a deal with Actelion Pharmaceuticals to help the company bolster its position in Asia.

Pfenex enters anthrax vaccines realm with $143.5M BARDA contract

While San Diego-based Pfenex's primary focus isn't on vaccines, the company gained a big backer in the space Monday with the announcement that the U.S. government has agreed to work with the biotech on its anthrax vaccine candidate for bioterror protection.

Singapore's Asian American Medical eyes oncology expansion in southern China

Singapore-listed Asian American Medical Group said it paid S$19.6 million ($13.9 million) to buy 60% of Rich Tree Land to develop an oncology diagnostics and treatment center in Zhuhai, southern China. 

Australia's TGA registers Hospira's Inflectra

Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.

HK-based Hutchison MediPharma sees Janssen exit from HMPL-507 candidate alliance

An exit by Janssen Pharmaceuticals from a seven year alliance with Hutchison MediPharma (HMP) to develop a novel inflammation/immunology candidate, HMPL-507, will see the HK-based firm carry-on independently, according to a press release.

Guardant Health teams with Flatiron for liquid biopsy-based drug development platform

Guardant Health has been charging full speed ahead with its liquid biopsy technology, inking deals and scoring new funds to expand the reach for its test. In its latest foray the company is teaming up with Flatiron Health to build a cloud-based platform that draws on its genomics data to accelerate cancer drug development.